Patient-Friendly Explanation

Zonisamide is a medication originally developed for epilepsy that was later found to help some patients lose weight as a side effect. It is thought to work by influencing brain chemicals that control appetite and food cravings. While not a first-line weight loss medication, it may be prescribed off-label or as part of a combination approach for patients who need additional support.

Clinical Definition

Zonisamide is a sulphonamide anticonvulsant with serotonergic and dopaminergic activity that modulates voltage-gated sodium and T-type calcium channels. Its weight-loss effect is likely mediated through enhanced serotonin and dopamine signalling in hypothalamic feeding centres, leading to reduced appetite and decreased food reward sensitivity. In clinical trials, zonisamide produced modest but statistically significant weight loss (3–7% of baseline body weight) and has been studied in combination with bupropion.

Why It Matters

Zonisamide expands the range of pharmacological options for patients who do not achieve adequate results with first-line medications or who experience intolerable side effects. Its unique mechanism and mood-stabilising properties may particularly benefit patients with comorbid depression or binge-eating tendencies. At NuLifeCare Singapore, our doctors evaluate each patient’s full clinical picture to determine whether adjunctive pharmacotherapy like zonisamide is appropriate.